In a filing with the US Securities and Exchange Commission (SEC), bluebird bio (Nasdaq: BLUE) has announced the departure of its chief medical officer, David Davidson.
The company said Dr Davidson would continue to be engaged as a consultant, “for a period of six months,” in order to provide “ongoing guidance and support for bluebird’s late-stage development programs in severe genetic disease.”
The Boston-based firm saw its shares tumble in February, after a suspected serious adverse reaction put a stop to trials into an experimental LentiGlobin gene therapy for sickle cell disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze